Streetbeat News

Analyst Ratings

ABVX

Morgan Stanley analyst Vikram Purohit has initiated coverage on Abivax with an Equal-Weight rating and set a price target of $15. Abivax is listed on NASDAQ under the ticker ABVX.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 1:09 pm

NYCB

Wedbush analyst David Chiaverini downgraded New York Community (NYSE:NYCB) from Neutral to Underperform and reduced the price target from $12 to $8.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 1:06 pm

WHD

Barclays analyst David Anderson has maintained an Overweight rating on Cactus (NYSE:WHD) but reduced the price target from $60 to $57.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 1:05 pm

DCBO

Over the past 3 months, 4 Wall Street analysts have published their opinions on Docebo Inc. (NASDAQ:DCBO), with 1 bullish, 2 somewhat bullish, and 1 indifferent rating. The average 12-month price target for Docebo is $50.5, with a high of $56.00 and a low of $44.00. This target has increased by 18.35% over the past month. Analysts provide ratings based on research and insights into company performance, although their predictions are opinions and subject to human error.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 1:00 pm

ACRS

Aclaris Therapeutics (NASDAQ:ACRS) has received a mix of bullish and indifferent analyst ratings over the last quarter, with no bearish ratings. The average 12-month price target for ACRS is $29.43, which is a significant increase from the previous target of $18.00. The high target is $43.00 and the low is $2.00. The increase in the average price target suggests a positive outlook from analysts.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 1:00 pm

UEC

Uranium Energy (AMEX:UEC) has received positive ratings from analysts in the last quarter, with 3 bullish and 1 somewhat bullish rating. The average price target is $7.25, which is higher than the current price of $5.94, indicating a potential upside. The average price target has increased by 3.57% from the previous target of $7.00. Analysts typically review stocks each quarter and their ratings are based on company performance, financial statements, and insider communications.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 1:00 pm

AKRO

11 Wall Street analysts have recently provided their opinions on Akero Therapeutics (NASDAQ:AKRO), with an average price target of $52.27, which is significantly higher than the current price of $13.95. The consensus among these analysts is positive, with 4 bullish and 7 somewhat bullish ratings. However, this target represents an 18.15% decrease from the previous target of $63.86. Analysts' ratings are based on comprehensive analysis, including company data and industry trends.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 1:00 pm

ANSS

Ansys (NASDAQ:ANSS) has received mixed analyst ratings in the last quarter, with an average price target of $309.25, which is 8.25% higher than the current price of $285.65. This target is a 10.75% decrease from the previous target of $346.50. Analysts' ratings are a mix of bullish, somewhat bullish, indifferent, and somewhat bearish, with no bearish ratings. These ratings are based on information from company calls, financial statements, and insider conversations.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 1:00 pm

AYX

Alteryx (NYSE:AYX) has received 8 analyst ratings in the last quarter with an average price target of $45.0, representing an upside from the current price of $37.3. The ratings include 4 bullish, 1 somewhat bullish, 1 indifferent, and 2 somewhat bearish. Over the past month, the average price target has increased by 38.46%. Analysts typically review stocks quarterly or after major company updates, basing their ratings on financial predictions and company performance.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 1:00 pm

ALLK

Barclays analyst Carter Gould has maintained an Underweight rating on Allakos (NASDAQ:ALLK) and reduced the price target from $2.5 to $1.5.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:59 pm